A5009340562- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Kruppel-like factors research
- Platelet Disorders and Treatments
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Hemoglobinopathies and Related Disorders
- Venous Thromboembolism Diagnosis and Management
- Abdominal Trauma and Injuries
- Blood Coagulation and Thrombosis Mechanisms
- Chronic Lymphocytic Leukemia Research
- COVID-19 Clinical Research Studies
- Appendicitis Diagnosis and Management
- Renal Diseases and Glomerulopathies
- Gallbladder and Bile Duct Disorders
- Protease and Inhibitor Mechanisms
- Cell Adhesion Molecules Research
- Respiratory Support and Mechanisms
- Pancreatitis Pathology and Treatment
- Multiple Myeloma Research and Treatments
- Blood properties and coagulation
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Medical and Biological Ozone Research
- Respiratory and Cough-Related Research
- Erythrocyte Function and Pathophysiology
University of Catania
2015-2024
Policlinico Universitario di Catania
2022
Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele
2014-2019
American College of Surgeons
2018
Cluster in Biomedicine
2011-2014
Ferrarotto Hospital
1983-2012
Ospedale "Santa Maria delle Croci" di Ravenna
2005
Southampton General Hospital
1998
Current treatment recommendations for patients with polycythemia vera call maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in randomized clinical trial.We randomly assigned 365 adults JAK2-positive who were being treated phlebotomy, hydroxyurea, or both to receive either more intensive (target hematocrit, <45%) (low-hematocrit group) 45 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular...
Background Prior thrombosis is a well-established risk factor for re-thrombosis in polycythemia vera and essential thrombocythemia but scarce data are available on the rate of optimal strategy prevention recurrence.Design Methods We retrospectively estimated recurrence multicenter cohort 494 patients (poly-cythemia vera/essential 235/259) with previous arterial (67.6%) or venous (31%) both (1.4%). First was cerebrovascular disease 191 cases, acute coronary syndrome 106, peripheral 44,...
Hydroxyurea (Hydroxycarbamide; HU) is commonly used for the long-term treatment of patients with Philadelphia-chromosome negative chronic myeloproliferative neoplasms (MPNs). It considered a first-choice agent these disorders as underlined by European Leukemia Net Consensus Conference [1], although it formally approved this indication in some countries only. The drug reportedly well tolerated large majority subjects, systemic and/or localized toxicities have been reported. criteria...
Coronavirus 2 (CoV-2) infection or coronavirus disease 2019 (COVID-19) is frequently associated with microvascular thrombosis.The microthrombosis in COVID-19 the result of interplay between inflammation and endotheliopathy. Elevated interleukin-6 (IL-6) characterizes resulting endotheliopathy coagulopathy marked by elevated D-dimer (DD). Aim this study to identify describe coagulation changes 100 moderate patients having lung involvement determine association severity prognosis....
There is evidence that leukocytosis associated with an increased risk of first thrombosis in patients polycythemia vera (PV) and essential thrombocythemia (ET). Whether it a factor for recurrent too currently unknown. In the frame multicenter retrospective cohort study, we recruited 253 PV (n = 133) or ET 120), who were selected on basis arterial (70%) venous major (27.6%) both (2.4%), not receiving cytoreduction at time thrombosis. The probability leukocyte count recorded was estimated by...
Eur J Clin Invest 2011; 41 (6): 616–626 Abstract Background Cigarette smoking is associated with cardiovascular morbidity and mortality. Exposure to cigarette smoke can cause endothelial dysfunction impaired endothelium‐dependent vasodilation ‘endothelial activation’, which predispose atherothrombosis. The effects of continued cessation on the level endothelial, platelet clotting activation have not been described previously. Here, we prospectively monitored changes in circulating...
To investigate the characteristics and clinical course of cerebral vein thrombosis (CVT) in patients with myeloproliferative neoplasms (MPN) we compared 48 MPN CVT (group MPN‐CVT) to 87 other venous MPN‐VT) 178 no MPN‐NoT) matched by sex, age at diagnosis (±5 years) type MPN. The study population was identified among 5,500 MPN, from January 1982 June 2013. Thrombophilia abnormalities were significantly more prevalent MPN‐CVT MPN‐VT than MPN‐NoT group ( P = 0.015), as well JAK2 V617F mutation...
One out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such we aimed at assessing the survival impact SC itself and MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 diagnosed concurrently or after MPN. Overall, 2995 person-years (PYs) accumulated mortality rate (MR) since diagnosis was 5.9 (5.1-6.9) deaths for every 100 PYs. A "poor prognosis" (stomach,...
What evaluation and care is offered to women after unexplained recurrent pregnancy loss (RPL) or intra-uterine foetal death (IUFD) what are the reproductive outcomes?Women assessed for thrombophilia often treated with low-molecular weight heparin (LMWH) and/or low-dose aspirin (ASA).Randomized controlled trials (RCTs) on possible efficacy of heparins have been inconclusive due limited power detect a difference patient heterogeneity.Prospective multicentre cohort study performed in 12...
Abstract We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or stroke (IS, 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs. The composite incidence of recurrent TIA IS, acute myocardial infarction (AMI), cardiovascular (CV) death was 4.21 19.2%, respectively at one five years after the index event, an estimate unexpectedly lower than reported in general population. Patients tended to...
Introduction: Portal vein thrombosis (PVT) could be a life-threatening complication after splenectomy if not diagnosed promptly and treated properly. Risk factors of PVT are completely clarified. Spleen size underlying hematologic diseases main potential risk for this complication. Laparoscopic surgery might increase the developing PVT, as it reduces blood flow in portal system due to pneumoperitoneum but, on other hand, seems associated with less postoperative modifications coagulation...
Background and Objectives:The aim of this study was to evaluate the results laparoscopic surgery performed for coexisting spleen gallbladder surgical diseases.Methods:Between May 2004 October 2012, 12 patients underwent concomitant splenectomy cholecystectomy. Indications included idiopathic thrombocytopenic purpura in 5 patients, hereditary spherocytosis 4 thalassemia intermedia 3 patients.Results:The mean operative time 100 minutes (range, 80–160 minutes), blood loss ranged from 0 150 mL...
Hyperresponsiveness of the airways to various spasmogenic stimuli is a characteristic feature bronchial asthma. However, association between different which asthmatic are hyperresponsive and inflammation not completely understood. We have investigated relationship airway hyperresponsiveness in asthma, as assessed by bronchoprovocation tests methacholine bradykinin, two well defined bronchoconstrictor agonists. Sputum induction hypertonic saline bradykinin challenges were performed 14...
We performed a retrospective study on patients with idiopathic thrombocytopenic purpura (ITP) to evaluate the response splenectomy in relation preoperative platelet count.Two groups of operated laparoscopic or open for ITP, count ≤30,000/μL (study group: 22 patients) and >30,000/μL (control 18 patients), respectively, were compared. The two homogeneous age, sex, length steroid therapy, time interval between diagnosis surgery (Student t test P > .1). results evaluated at one year after...